Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta’s Elevidys.
Makary pushes for IRB reforms to catch China’s speedy trial starts
The process by which institutional review boards oversee clinical trials needs reforms that are “big and different” so that the US can keep pace with


